[An open-label non-comparative study of the efficacy and safety of melaxen in treatment of sleep disorders in alcohol dependent patients during the period of abstinence].
Forty-five alcohol dependent patients with sleep and mild affective disorders were treated with melaxen (melatonin IR) for 3-weeks. All subjects did not use alcohol for at least 14 days prior the trial. The battery of psychometric scales (a subjective sleep quality questionnaire, the Epworth sleepiness scale, a sleep apnea screening questionnaire, HAM-A, HAM-D, an alcohol consumption questionnaire) was used. Melaxen distinctly improved sleep latency, quality and duration of sleep, breathing during sleep. The drug decreased daily sleepiness and affective disorders, particularly, anxiety. The dosage of melaxen ranged from 3 to 6 mg depending on the respond to the minimal dose.